Europe’s Stoxx 600 inches lower amid French political crisis
Director Alan Grujic of Guided Therapeutics Inc (NASDAQ:GTHP), a $23.24 million market cap company, acquired 152,108 shares of common stock on August 29, 2025. The shares were purchased through a transaction valued at $0. The stock, currently trading at $0.28, has shown remarkable strength with a 192% gain over the past six months.
According to a Form 4 filing with the Securities and Exchange Commission, Grujic also acquired 152,108 warrants. These warrants are exercisable for common stock and have an exercise price of $0.25 per share, expiring in four years. While the company is not currently profitable, InvestingPro analysis reveals 10+ additional key metrics and insights about GTHP’s financial health and valuation.
On August 21, 2025, Grujic acquired 17,408 shares of common stock and 200,000 shares of common stock. Also on August 21, Grujic disposed of 50 shares of Preferred Series E Stock. The company maintains a moderate debt level and operates with a gross profit margin of 65%.
In other recent news, Guided Therapeutics, Inc. has announced the completion of patient enrollment for its clinical study of the LuViva Advanced Cervical Scan. The study has successfully reached approximately 430 patients across four participating clinics. The company is now moving forward with data analysis, which involves an external review of biopsy samples, processing case report forms, and conducting statistical analysis according to the study protocol. This development marks a significant step in the clinical evaluation of the LuViva Advanced Cervical Scan. Once the analysis is complete, all clinical sites will cease enrolling new patients. These recent developments highlight Guided Therapeutics’ progress in its clinical research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.